Research Papers

25 of 388 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Early transmural healing and its predictors assessed by magnetic resonance enterography in patients with Crohn's diseas…
Zhou L; Hu C; Zhang R; Qiu Y; Wang Y; Liu Z; Chen B; He Y; Zeng Z; Li X; Mao R; Chen M.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Rescue therapy for refractory <i>Helicobacter pylori</i> infection: current status and future concepts.
Wang SW; Yu FJ; Kuo FC; Wang JW; Wang YK; Chen YH; Hsu WH; Liu CJ; Wu DC; Kuo CH.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn's dise…
Kim ES; Kwon Y; Choe YH; Kim MJ.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.
Jeong SY; Hong JY; Park JO; Park YS; Lim HY; Jang JY; Jeon Y; Kim ST.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Real-world outcomes associated with vonoprazan-based <i>versus</i> proton pump inhibitor-based therapy for <i>Helicobac…
Howden CW; Cook EE; Swallow E; Yang K; Guo H; Pelletier C; Jacob R; Sugano K.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Therapeutic eradication choices in <i>Helicobacter pylori</i> infection in children.
Manfredi M; Gargano G; Gismondi P; Ferrari B; Iuliano S.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
IBD barriers across the continents: a continent-specific analysis: Latin America.
Queiroz NSF; Martins CA; Quaresma AB; Olivera Sendra PA; Ernest-Suarez K; Kotze PG.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The natural history of histological changes in microscopic colitis.
Sehgal K; Tome J; Kamboj AK; Dierkhising RA; Pardi DS; Khanna S.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Effect of peripartum <i>Clostridioides difficile</i> infection on pregnancy and neonatal outcomes: an observational stu…
Saha S; Pardi R; Theiler RN; Pardi DS; Khanna S.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
The treatment principles and targets for intestinal Behcet's disease.
He K; Wu D.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Early predictive value of scoring systems and routine laboratory tests in severity and prognosis of acute pancreatitis …
Wang Y; Qu G; Wu Z; Tian D; Yang W; Li H; Lu Y; Meng G; Zhang H.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Gastrointestinal injury induced by immunomodulators: A review article.
Zhang P; Mao R; Zhang C; Qiu Y; Chen M.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Neutrophil-to-lymphocyte ratio for predicting postoperative recurrence in Crohn's disease patients with isolated anasto…
Chen R; Li C; Chao K; Tie Y; Zheng J; Guo H; Zeng Z; Li L; Chen M; Zhang S.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Gastric peroral endoscopic pyloromyotomy (G-POEM) in patients with refractory gastroparesis: a review.
McCurdy GA; Gooden T; Weis F; Mubashir M; Rashid S; Raza SM; Morris J; Cai Q.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Implications of the paradigm shift in management of <i>Helicobacter pylori</i> infections.
Graham DY.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter co…
Shin SH; Oh K; Hong SN; Lee J; Oh SJ; Kim ES; Na SY; Kang SB; Koh SJ; Bang KB; Jung SA; Jung SH; Kim KO; Park SH; Yang SK; Choi CH; Ye BD.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar …
Bouhnik Y; Fautrel B; Beaugerie L; Pelletier AL; Martinez-Vinson C; Freudensprung U; Brigui A; Addison J.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis.
Ernest-Suarez K; Panaccione R.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Prevention of post-ERCP pancreatitis: current strategies and novel perspectives.
Borrelli de Andreis F; Mascagni P; Schepis T; Attili F; Tringali A; Costamagna G; Boškoski I.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Effect of antidepressants on psychological comorbidities, disease activity, and quality of life in inflammatory bowel d…
Wang L; Liang C; Chen P; Cao Y; Zhang Y.
Therap Adv Gastroenterol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
An explainable artificial intelligence system for diagnosing <i>Helicobacter Pylori</i> infection under endoscopy: a ca…
Zhang M; Pan J; Lin J; Xu M; Zhang L; Shang R; Yao L; Li Y; Zhou W; Deng Y; Dong Z; Zhu Y; Tao X; Wu L; Yu H.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Characteristics of fecal microbiota in different constipation subtypes and association with colon physiology, lifestyle…
Yu T; Ding Y; Qian D; Lin L; Tang Y.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Efficacy and safety of medical therapies in microscopic colitis: a systematic review and network meta-analysis.
Kumar A; Hiner G; Brookes MJ; Segal JP.
Therap Adv Gastroenterol (Unknown)
Published: 2023
3/6 Transparent
Funding Declared
Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerativ…
Eder P; Kłopocka M; Cichoż-Lach H; Talar-Wojnarowska R; Kopertowska-Majchrzak M; Michalak A; Filip R; Waszak K; Stawczyk-Eder K; Janiak M; Skrobot K; Liebert A; Zatorski H; Solarska-Półchłopek A; Krogulecki M; Pękała A; Poniewierka E; Smoła I; Kaczka A; Wojciechowski K; Drygała S; Zagórowicz E.
Therap Adv Gastroenterol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared
The efficacy and safety of <i>Saccharomyces boulardii</i> in addition to antofloxacin-based bismuth quadruple therapy f…
He XJ; Wang XL; Sun DJ; Huang XY; Liu G; Li DZ; Lin HL; Zeng XP; Li DL; Wang W.
Therap Adv Gastroenterol (Unknown)
Published: 2023
4/6 Transparent
Registered Funding Declared